Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 11 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 9029525

    Compositions and methods for inhibiting expression of GSK-3 genes

    Alnylam Pharmaceuticals, Inc. · Granted May 12, 2015 · Expires May 7, 2035

    granted

  2. US 9012498

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 21, 2015 · Expires Apr 16, 2035

    granted

  3. US 9012624

    Compositions and methods for inhibiting expression of a gene from the JC virus

    Alnylam Pharmaceuticals, Inc. · Granted Apr 21, 2015 · Expires Apr 16, 2035

    granted

  4. US 9006197

    Compositions and methods for inhibiting expression of Eg5 and VEGF genes

    Alnylam Pharmaceuticals, Inc. · Granted Apr 14, 2015 · Expires Apr 9, 2035

    granted

  5. US 9000143

    Compositions and methods for inhibiting expression of IKK-B gene

    Alnylam Pharmaceuticals, Inc. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted

  6. US 8993746

    Nuclease resistant double-stranded ribonucleic acid

    Alnylam Pharmaceuticals, Inc. · Granted Mar 31, 2015 · Expires Mar 26, 2035

    granted

  7. US 8987377

    Poly(amide) polymers for the delivery of oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Mar 24, 2015 · Expires Mar 19, 2035

    granted

  8. US 8987227

    Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of use

    Alnylam Pharmaceuticals, Inc. · Granted Mar 24, 2015 · Expires Mar 19, 2035

    granted

  9. US 8962580

    Chemical modifications of monomers and oligonucleotides with cycloaddition

    Alnylam Pharmaceuticals, Inc. · Granted Feb 24, 2015 · Expires Feb 19, 2035

    granted

  10. US 8957223

    Ligand-conjugated monomers

    Alnylam Pharmaceuticals, Inc. · Granted Feb 17, 2015 · Expires Feb 12, 2035

    granted

  11. US 8889644

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Nov 18, 2014 · Expires Nov 13, 2034

    granted

  12. US 8877917

    Glycoconjugates of RNA interference agents

    Alnylam Pharmaceuticals, Inc. · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted

  13. US 8877726

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted

  14. US 8859750

    RNAi modulation of RSV and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Oct 14, 2014 · Expires Oct 9, 2034

    granted

  15. US 8859516

    Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes

    Alnylam Pharmaceuticals, Inc. · Granted Oct 14, 2014 · Expires Oct 9, 2034

    granted

  16. US 8828956

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Sep 9, 2014 · Expires Sep 4, 2034

    granted

  17. US 8809516

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted Aug 19, 2014 · Expires Aug 14, 2034

    granted

  18. US 8809292

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 19, 2014 · Expires Aug 14, 2034

    granted

  19. US 8796436

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  20. US 8791250

    Compositions and methods for inhibiting expression of the HAMP gene

    Alnylam Pharmaceuticals, Inc. · Granted Jul 29, 2014 · Expires Jul 24, 2034

    granted

  21. US 8765932

    Compositions and methods for inhibiting expression of XBP-1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Jul 1, 2014 · Expires Jun 26, 2034

    granted

  22. US 8754201

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted Jun 17, 2014 · Expires Jun 12, 2034

    granted

  23. US 8741866

    Compositions and methods for inhibiting expression of transthyretin

    Alnylam Pharmaceuticals, Inc. · Granted Jun 3, 2014 · Expires May 29, 2034

    granted

  24. US 8729037

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted May 20, 2014 · Expires May 15, 2034

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.